Harmony Biosciences Holdings (HRMY) Cost of Revenue (2019 - 2026)

Harmony Biosciences Holdings' Cost of Revenue history runs 8 years deep, the most recent figure standing at $44.5 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 44.94% year-over-year to $44.5 million; the TTM figure through Mar 2026 stood at $132.0 million (up 33.44% YoY), while the FY2025 annual figure was $119.5 million, up 7.75% from the prior year.
• Cost of Revenue came in at $44.5 million for Q1 2026 at Harmony Biosciences Holdings, up from -$10.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $59.6 million in Q3 2025 to a low of -$10.3 million in Q4 2025.
• A 5-year average of $25.8 million and a median of $26.9 million in 2022 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue soared 313.04% in 2022 and slumped 220.86% in 2025, its largest moves.
• Harmony Biosciences Holdings' Cost of Revenue stood at $26.9 million in 2022, then climbed by 0.0% to $26.9 million in 2023, then plunged by 68.35% to $8.5 million in 2024, then plunged by 220.86% to -$10.3 million in 2025, then surged by 532.79% to $44.5 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $44.5 million, -$10.3 million, and $59.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison